BioVie Inc. (BIVI) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
BioVie Inc. (BIVI) Bundle
Looking to assess the intrinsic value of BioVie Inc.? Our (BIVI) DCF Calculator integrates real-world data with comprehensive customization features, allowing you to refine your forecasts and enhance your investment choices.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -2.5 | -137.8 | -23.7 | -45.7 | -32.0 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Depreciation | .2 | .2 | .2 | .3 | .2 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -2.7 | -138.0 | -23.9 | -46.0 | -32.2 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Total Cash | .0 | 4.5 | 18.6 | 33.9 | 23.8 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | 1.3 | 1.0 | .0 | .0 | 3.6 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -5.5 | -194.8 | -23.9 | -46.0 | -32.2 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -4.0 | -194.9 | -24.7 | -45.7 | -28.4 | -3.6 | .0 | .0 | .0 | .0 |
WACC, % | 23.72 | 23.72 | 23.72 | 23.72 | 23.72 | 23.72 | 23.72 | 23.72 | 23.72 | 23.72 |
PV UFCF | ||||||||||
SUM PV UFCF | -2.9 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -3 | |||||||||
Net Debt | -18 | |||||||||
Equity Value | 15 | |||||||||
Diluted Shares Outstanding, MM | 5 | |||||||||
Equity Value Per Share | 3.28 |
What You Will Get
- Real BIVI Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess BioVie Inc.'s future performance.
- User-Friendly Design: Designed for professionals while remaining easy to navigate for newcomers.
Key Features
- 🔍 Real-Life BIVI Financials: Pre-filled historical and projected data for BioVie Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate BioVie’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize BioVie’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Access the Model: Download and open the Excel file containing BioVie Inc.'s (BIVI) financial data.
- 2. Adjust Parameters: Modify essential inputs such as growth projections, WACC, and capital investments.
- 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate various forecasts to investigate different valuation scenarios.
- 5. Present with Assurance: Share professional valuation findings to back your strategic decisions.
Why Choose BioVie Inc. (BIVI)?
- Innovative Solutions: Focused on developing novel therapies for liver disease and neurodegenerative disorders.
- Strong Pipeline: A diverse range of clinical-stage products aimed at addressing unmet medical needs.
- Expert Team: Led by seasoned professionals with extensive experience in biotechnology and pharmaceuticals.
- Robust Partnerships: Collaborations with leading research institutions and industry partners enhance development capabilities.
- Commitment to Quality: Adheres to the highest standards of research and development to ensure patient safety and efficacy.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for portfolio evaluation of BioVie Inc. (BIVI).
- Corporate Finance Teams: Examine valuation scenarios to inform strategic decisions within their organizations.
- Consultants and Advisors: Deliver precise valuation insights to clients regarding BioVie Inc. (BIVI).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech firms like BioVie Inc. (BIVI) are assessed in the market.
What the Template Contains
- Preloaded BIVI Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.